Audited Financial Results for the year ended March 31, 2025
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.9 pts less than Nifty Microcap 250 and 5.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Marksans Pharma Limited has filed its audited financial results for the full year ended March 31, 2025, with the stock exchange. Annual results filings typically include audited consolidated and standalone figures for revenue, expenses, operating profit, profit after tax, and balance sheet highlights as reviewed by statutory auditors. The actual line-item figures (revenue, EBITDA, PAT, margins, and EPS) are contained in the detailed results document accompanying this filing. Investors should refer to the full PDF for exact numbers and segment-wise performance. Comparison with the previous year's audited results would indicate year-on-year growth or decline.
This is a routine regulatory disclosure of full-year audited performance and is not an action-trigger event in itself; the market reaction will depend entirely on how the reported revenue, margins, and PAT compare with street expectations and prior-year numbers.